Office-based lab marketing: vascular center claims, referrals, investors and the OIG report

An office-based lab, or OBL, is a procedure suite inside a physician practice where vascular surgeons, interventional cardiologists or interventional radiologists treat peripheral artery disease (PAD) with angioplasty, stents and atherectomy. Outpatient vascular centers market these labs to two audiences: patients with leg pain or foot wounds, and the primary care, podiatry and wound care clinicians who refer them. In May 2026 the HHS Office of Inspector General published a report on how these procedures are billed in OBLs, and its findings bear directly on what an OBL’s marketing should and should not say. This guide is for vascular practices, OBL owners and investors, and the agencies that write their pages, ads and referral outreach.

Two related topics have their own guides and are not repeated here. Marketing for varicose and spider vein treatment, including free vein screenings and cosmetic versus covered care, is in our vein clinic marketing guide. Marketing for Medicare-certified surgery centers, including physician ownership and the ASC safe harbor in detail, is in our ambulatory surgery center marketing guide.

What the May 2026 OIG report says

The OIG report (OEI-01-24-00250, issued May 4, 2026) looked at Medicare Part B payments for peripheral vascular procedures, meaning angioplasty, stenting and atherectomy used to relieve leg pain from narrowed or blocked arteries. An OBL owner planning a campaign should know what it found, because marketing can feed the patterns that concern OIG.

The points from the report that matter for marketing are these:

• OIG states that Medicare Part B pays physicians more when they perform these procedures in an OBL than in other settings, and that OBLs are generally owned by a physician or physician group, with facility costs included in the physician payment.
• OIG notes that professional guidelines issued in 2015 and 2024 recommend trying conservative treatment first, through medications and lifestyle changes such as exercise and quitting smoking, because treating early stages of PAD with procedures may cause harm.
• OIG says overuse of these procedures may lead to Medicare paying for medically unnecessary services and to risks for patients, such as amputation.
• From 2019 through 2023, OIG found that procedures shifted from hospital outpatient departments to OBLs, and it flagged OBL billing patterns that may indicate medically unnecessary procedures, including treating a high share of patients with early-stage PAD.
• OIG recommended that CMS monitor billing for procedures that may be medically unnecessary and follow up on the physicians it identified. CMS concurred with both recommendations.

None of this says an OBL is improper. It does mean that an OBL’s ads, landing pages and referral materials may be read alongside its billing data, by payers, auditors and, if it comes to that, a court. Marketing that pulls in patients with mild symptoms and promises a procedure as the answer is the pattern the report describes.

Describe PAD care the way NHLBI does

The National Heart, Lung, and Blood Institute’s PAD treatment page (last updated March 24, 2022) says treatment depends on how severe the disease is, and that a provider may recommend heart-healthy lifestyle changes, an exercise program, medicine, or a procedure to open or bypass blockages. It says that if lifestyle changes, an exercise program and medicines do not work well enough, the provider may recommend a procedure or surgery. It names smoking as the main risk factor for PAD.

A vascular center’s patient pages can follow that order without losing anything. Practical ways to do it:

• Present the full range of care the practice offers, including exercise programs, medicines and risk factor management, before procedures.
• Say that the treatment plan depends on the evaluation, and that not every patient with leg pain needs a procedure.
• Name procedures plainly (angioplasty, stenting, atherectomy, bypass) and describe what each one is, using the NHLBI wording as a guide.
• Put the risks of procedures, approved by your physicians, on the same page as the benefits.
• Link to the NHLBI pages so patients can read an independent source.

Limb salvage and amputation claims

Vascular marketing reaches for words about legs: “limb salvage”, “avoid amputation”, “save your leg”. They are also outcome claims. Under 15 U.S.C. 45 and 15 U.S.C. 52, deceptive acts and false advertisements for services and devices are unlawful, and the FTC’s Health Products Compliance Guidance (HPCG) explains how the FTC applies those laws to health claims.

Three points from the HPCG apply directly:

• Claims about health benefits or safety need competent and reliable scientific evidence, and the HPCG says that, as a general matter, this will need to be randomized, controlled human clinical testing.
• When an ad can reasonably be read more than one way, the advertiser has to substantiate each reading. “Avoid amputation” can be read as a promise that a procedure at this center will prevent one.
• Anecdotes about individual experiences, including patient surveys, are not enough to substantiate a health claim.

The NHLBI pages give context that cuts both ways. The Living With page says people who smoke or have diabetes have a much higher risk of complications from PAD, including losing a limb, and that acute limb ischemia is a medical emergency that must be treated rapidly to avoid amputation. The OIG report, for its part, lists amputation among the risks of overusing procedures. A headline that ties a procedure to avoiding amputation, without the evidence and the context, is the kind of claim the HPCG asks advertisers to substantiate for every reasonable reading.

Safer ways to talk about the same subject:

• Describe the service: “evaluation and treatment for PAD, including advanced disease and foot wounds”.
• Describe the team and the process: who evaluates the patient, how the wound care, podiatry and vascular teams coordinate, and how follow-up works.
• If you publish outcome figures, state the method, the period, the patient group and who measured them, or quote a dated, attributed source. Do not publish a limb salvage rate you cannot support.
• Keep urgent warning signs as patient education (when to call 911 or go to the emergency department), not as a scare tactic in an ad.

Who the ads should reach

A PAD campaign may target adults with leg pain or cramping when walking. Because the OIG report flags billing for a high share of patients with early-stage PAD, an OBL campaign built to fill the schedule with mild cases deserves a second look before it runs. A few choices keep the campaign closer to appropriate care:

• Invite an evaluation, not a procedure. “Leg pain when you walk? Get it evaluated” is a different ad from “Clear your arteries in an hour”.
• Avoid ads and quizzes that tell a reader they have PAD or need treatment based on symptoms alone.
• Keep health information out of ad tracking on forms and landing pages, and review any symptom quiz with that in mind.
• Treat free screening events with care: federal beneficiary inducement rules can apply to free services offered to Medicare and Medicaid patients. Our health fair and screening event guide covers the details.

Referral outreach to primary care, podiatry and wound care

An OBL depends on referrals, so outreach to referring clinicians is part of its marketing. Lunch-and-learns, referral pads, gift baskets and direct mail to clinics are all forms this takes. For patients covered by federal health care programs, 42 U.S.C. 1320a-7b(b) makes it a crime to knowingly and willfully offer or pay any remuneration, directly or indirectly, in cash or in kind, to induce a referral for items or services paid for by those programs.

In practice, that means counsel should review the following before they start:

• Meals, gifts, tickets or anything of value given to referring clinicians or their staff.
• Paid speaking, consulting or medical director roles for physicians who also refer patients.
• Free services to referring offices, such as staff, testing equipment or wound care supplies.
• Payments to marketers or lead vendors based on the number of patients referred or procedures performed.

Accurate, useful referral materials need no payment: a clear description of what the center treats, how to refer, how fast patients are seen, and how results come back to the referring clinician. Our guide to patient and physician referrals covers referral programs in more depth.

Physician investors and ownership disclosure

OBLs, like ambulatory surgery centers, can be owned by groups of physicians, and a venture may invite referring physicians to invest. Two federal laws are relevant, and both are fact-specific.

The first is the anti-kickback statute above. Its safe harbor for investment returns in surgery centers, at 42 CFR 1001.952(r), applies by its terms when the investment entity is a certified ambulatory surgical center under 42 CFR part 416, and one of its conditions is that patients referred to the entity by an investor are fully informed of the investor’s investment interest. An OBL that is not a certified ASC should not assume that safe harbor applies, and counsel should review how investment returns are structured.

The second is the physician self-referral law. 42 U.S.C. 1395nn(a) says that if a physician, or an immediate family member, has a financial relationship with an entity, the physician may not refer Medicare patients to that entity for designated health services, and the entity may not bill for them, unless an exception applies. Whether a given lab’s services or ownership fall under it is a question for counsel. State laws on self-referral and fee splitting apply as well, set state by state.

For marketing, the practical rule is simple: do not hide ownership. If physicians who refer patients have an interest in the center, say so where it matters, and never describe the center as independent or unbiased when it is not.

Patient stories and device claims

Stories of a healed wound or a walk without pain are strong in this category. Under 16 CFR 255.2(a), the advertiser must substantiate claims made through consumer endorsements as if it had made them directly, and consumer endorsements themselves are not competent and reliable scientific evidence. Under 255.2(b), an endorsement about a key attribute will likely be read as representing what consumers will generally achieve, so without substantiation for that, the ad should clearly and conspicuously disclose the generally expected performance.

Using a patient’s protected health information in marketing needs a written authorization under 45 CFR 164.508(a)(3). Get it before filming, keep it with the asset, and stop using the story if the patient revokes it. Wound photos are protected health information like any other.

Leave device brands out of ads, and do not describe a device as better, safer or newer than another without substantiation. The OIG report notes that some research indicates atherectomy may not be more effective than angioplasty and stents and has a higher risk of complications, so “the latest technology” is not a benefit claim on its own. Our medical device marketing claims guide covers device wording.

Illustration: two ways to advertise an outpatient vascular center

Illustration: [Practice name] runs a search ad that reads “Leg pain? Avoid amputation. Same-week artery clearing, no hospital stay.” The landing page lists atherectomy first, shows a patient story with no disclosure, and has a symptom quiz that ends with “You may need a procedure. Book now.” The ad makes an outcome promise it cannot substantiate, the quiz tells readers they need treatment based on symptoms alone, and the campaign is built to bring in the early-stage patients for whom, as the OIG report notes, guidelines recommend trying conservative treatment first.

Illustration: [Practice name] runs an ad that reads “Leg pain when you walk? See a vascular specialist. Evaluation for PAD and foot wounds.” The landing page explains PAD, lists exercise, medicine, risk factor care and procedures in that order, names who performs procedures and where, puts risks next to benefits, links to the NHLBI pages, and states which physicians hold an ownership interest in the lab. The patient story has written authorization and a disclosure of generally expected results.

Checklist before an OBL campaign goes live

• Pages present lifestyle changes, exercise programs and medicines as well as procedures, and say the plan depends on the evaluation.
• No “avoid amputation”, “save your leg” or limb salvage promises; outcome figures only with a stated method or a dated, attributed source.
• Ads invite an evaluation and do not tell readers they need a procedure based on symptoms.
• Procedure risks, approved by your physicians, sit next to the benefits.
• Gifts, meals, paid roles, free services and per-referral payments to referral sources have been reviewed by counsel.
• Investor and ownership relationships are reviewed by counsel and disclosed to patients where it matters.
• No device brands or unsupported “latest technology” claims.
• Patient stories and wound photos have written authorization and a generally expected results disclosure where needed.
• Forms and quizzes keep health information away from ad tracking tools.

How we help

We build websites, local search, Google Ads and AI front desk tools for independent practices and health businesses. For a vascular practice or office-based lab, that means PAD pages that show the full range of care, ads that invite an evaluation rather than promise an outcome, and appointment and referral forms that keep health information away from tracking tools. We do not decide which patient needs a procedure, how a lab is owned, or whether a referral or investment arrangement is lawful; your physicians and counsel do. Our tools are built with HIPAA in mind. We confirm in writing what a BAA covers before any patient information flows through a tool, and if it is not covered, we do not route patient information through it. We are not a healthcare provider and we do not give legal or medical advice. We do not sell lead lists and we do not pay for referrals. For the wider rules, see our healthcare marketing rules hub.

Sources

• HHS OIG: Utilization Trends and Medicare Part B Billing for Office-Based Peripheral Vascular Procedures Raise Questions About Program Integrity (OEI-01-24-00250, May 4, 2026)
• NHLBI: Peripheral Artery Disease, Treatment
• NHLBI: Peripheral Artery Disease, Living With
• 15 U.S.C. 45: Unfair methods of competition and unfair or deceptive acts or practices
• 15 U.S.C. 52: Dissemination of false advertisements
• FTC: Health Products Compliance Guidance (December 2022)
• 16 CFR 255.2: Consumer endorsements
• 42 U.S.C. 1320a-7b: Criminal penalties for acts involving Federal health care programs
• 42 CFR 1001.952: Exceptions (safe harbors), paragraph (r) ambulatory surgical centers
• 42 U.S.C. 1395nn: Limitation on certain physician referrals
• 45 CFR 164.508: Uses and disclosures for which an authorization is required

More in Facilities, care services and pharmacy